

latanoprost (Xalatan)

(No. 102/04)

Pfizer

Summary of Recommendation

12 July 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE: following a full submission.

Latanoprost (Xalatan[®]) is accepted for restricted use within NHS Scotland for the treatment of raised intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Use of latanoprost, as monotherapy, should be restricted to patients who have contraindications to beta-blockers or have a history of adverse reactions to this group of drugs. It may also be indicated in addition to beta-blockers when required.

It is one of a number of topical ocular prostaglandin analogue preparations licensed in the UK for this indication. In reducing IOP it is comparable in effect to other drugs in its class.

Professor David Webb
Deputy Chairman